RECRUITINGINTERVENTIONAL
Value of Screening MRI Brain in Stage IV Non-small Cell Lung Cancer
ValUe of Screening MRI Brain in Patients With Newly Diagnosed Stage IV Non-oncogene Addicted Non-small Cell Lung CANcer - The VULCAN Trial
About This Trial
Patients with newly diagnosed stage IV non-oncogene addicted NSCLC, who are fit for systemic treatment and don't have any symptoms of brain disease will undergo an MRI of the brain to screen for brain disease.
Who May Be Eligible (Plain English)
Who May Qualify:
- diagnosed by tissue sample (biopsy-confirmed) stage IV metastatic NSCLC, not amenable to curative treatment.
- Fit for systemic treatment (PS 0-2) according to standard of care.
- No symptoms of brain disease disease assessed according to standard clinical care by the thoracic oncologist.
Who Should NOT Join This Trial:
- Prior/concomitant therapy for stage IV disease.
- Oncogenic diver mutation (e.g. EGFR, ALK, ROS1, RET, MET, and BRAF) with approved targeted treatment.
- Contraindications for MRI scan with contrast as per standard of care protocol of the institution.
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Histologically or cytologically confirmed stage IV metastatic NSCLC, not amenable to curative treatment.
* Fit for systemic treatment (PS 0-2) according to standard of care.
* No symptoms of brain disease disease assessed according to standard clinical care by the thoracic oncologist.
Exclusion Criteria:
* Prior/concomitant therapy for stage IV disease.
* Oncogenic diver mutation (e.g. EGFR, ALK, ROS1, RET, MET, and BRAF) with approved targeted treatment.
* Contraindications for MRI scan with contrast as per standard of care protocol of the institution.
Treatments Being Tested
DIAGNOSTIC_TEST
MRI
MRI scan of the brain
Locations (1)
University Medical Center Groningen
Groningen, Netherlands